Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 2/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089310 | 0.91 | EPHX2 (0.33) | EPHX2MEN1KMT2ALSSMLYCD | |
| SCHEMBL21089309 | 0.87 | CTSK (0.34) | GPR119MLYCD | |
| SCHEMBL7585222 | 0.80 | BTK (0.41) | EPHX2MEN1KMT2A | |
| SCHEMBL7585234 | 0.80 | BTK (0.41) | EPHX2MEN1KMT2A | |
| SCHEMBL17271531 | 0.77 | RECQL (0.45) | GPR119JAK2JAK1 | |
| SCHEMBL2606995 | 0.77 | MEN1 (0.40) | EPHX2MEN1KMT2ASTING1CHRM2 | |
| SCHEMBL13744654 | 0.76 | TDP1 (0.33) | GPR119JAK2JAK1 | |
| SCHEMBL14237883 | 0.75 | KMT2A (0.54) | EPHX2MEN1KMT2ASTING1HDAC3 | |
| SCHEMBL1495989 | 0.75 | EPHX1 (0.49) | MEN1KMT2A | |
| SCHEMBL9199990 | 0.74 | KMT2A (0.37) | EPHX2MEN1KMT2ASTING1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2023-11-23 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11712481-B2 | Lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-08-01 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712481-B2 | Lipid nanoparticle formulations | LIPA, PLIN3, PLIN1 | EPHX2 1934/4885MEN1 2116/4885KMT2A 2733/4885 |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | LIPA, PLIN3, PLIN1 | EPHX2 1934/4885MEN1 2116/4885KMT2A 2733/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | EPHX2 3620/4885MEN1 3812/4885KMT2A 4184/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | EPHX2 3620/4885MEN1 3812/4885KMT2A 4184/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | EPHX2 3620/4885MEN1 3812/4885KMT2A 4184/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | EPHX2 3850/4885MEN1 4026/4885KMT2A 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.